{"id":744898,"date":"2014-11-17T08:30:00","date_gmt":"2014-11-17T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/"},"modified":"2023-03-22T00:04:48","modified_gmt":"2023-03-22T04:04:48","slug":"merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/","title":{"rendered":"Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today"},"content":{"rendered":"<p class=\"bwalignc\">       Data are Embargoed by American Heart Association until 10:45 AM CT        Today     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today said that IMPROVE-IT met its primary endpoint. The results are<br \/>\n      scheduled to be presented at the American Heart Association Scientific<br \/>\n      Sessions later today. The data are embargoed by the American Heart<br \/>\n      Association until the start of the late-breaking clinical trials session<br \/>\n      at 10:45 a.m. CT today.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=50985010&amp;newsitemid=20141117005264&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=df644312b2b492b7055ace5dfad6fa72\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=50985010&amp;newsitemid=20141117005264&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=dca6fb921792a0b3cfc7b76817a87b39\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=50985010&amp;newsitemid=20141117005264&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=02028116e8b1199b11faec45ae6e842e\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=50985010&amp;newsitemid=20141117005264&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=0897e277a50ecc615e207a1aa6a6e841\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50985010&amp;newsitemid=20141117005264&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=75042c76f33f6ab4c32657e90106a4d2\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141117005264r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media Contact:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Investor        Contact:<br \/>Joe Romanelli, 908-423-5185     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Data are Embargoed by American Heart Association until 10:45 AM CT Today Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today. About Merck Today&#8217;s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit vip2-msd.com\/merckcom-migrated and connect with us on Twitter,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-744898","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Data are Embargoed by American Heart Association until 10:45 AM CT Today Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today. About Merck Today&#039;s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit vip2-msd.com\/merckcom-migrated and connect with us on Twitter,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141117005264r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\\\/\",\"name\":\"Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141117005264r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2014-11-17T08:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141117005264r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20141117005264r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today - Merck.com","og_description":"Data are Embargoed by American Heart Association until 10:45 AM CT Today Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today. About Merck Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit vip2-msd.com\/merckcom-migrated and connect with us on Twitter,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:48+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141117005264r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/","name":"Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141117005264r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2014-11-17T08:30:00+00:00","dateModified":"2023-03-22T04:04:48+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141117005264r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141117005264r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at-american-heart-association-scientific-sessions-today\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"ce4d6dc0-4d7c-43f8-9fe5-2e44a3bf4416","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-that-IMPROVE-IT-Achieved-Primary-Endpoint-Data-to-be-Presented-at-American-Heart-Association-Scientific-Sessions-Today-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744898\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744898"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}